Stockscreener 앱 받기
14.55
0.65%
-0.095
시간 외 거래:
14.56
0.005
+0.03%
전일 마감가:
$14.65
열려 있는:
$14.55
하루 거래량:
584.36K
Relative Volume:
0.56
시가총액:
$579.12M
수익:
-
순이익/손실:
$-168.05M
주가수익비율:
-2.8372
EPS:
-5.13
순현금흐름:
$-146.15M
1주 성능:
+2.07%
1개월 성능:
+45.84%
6개월 성능:
-76.74%
1년 성능:
-75.97%
1일 변동 폭
$14.16
$14.80
1주일 범위
$14.01
$14.82
52주 변동 폭
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
명칭
Keros Therapeutics Inc
전화
617-314-6297
주소
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
KROS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
14.55 | 579.12M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-21 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-12-16 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-12-16 | 재확인 | Oppenheimer | Outperform |
| 2024-12-13 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-12 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-12-12 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2024-12-12 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | 개시 | Jefferies | Buy |
| 2024-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-09-23 | 개시 | Guggenheim | Buy |
| 2024-06-25 | 개시 | Oppenheimer | Outperform |
| 2024-02-21 | 개시 | William Blair | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-07-31 | 개시 | Wedbush | Outperform |
| 2023-07-26 | 개시 | BofA Securities | Buy |
| 2023-02-14 | 개시 | Cowen | Outperform |
| 2022-10-18 | 개시 | Truist | Buy |
| 2022-07-26 | 개시 | BTIG Research | Buy |
| 2020-12-08 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-04 | 개시 | H.C. Wainwright | Buy |
| 2020-05-04 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2020-05-04 | 개시 | SVB Leerink | Outperform |
모두보기
Keros Therapeutics Inc 주식(KROS)의 최신 뉴스
(KROS) Long Term Investment Analysis - news.stocktradersdaily.com
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Alkeon Capital Management LLC - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Acquired by Barclays PLC - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Position Lifted by Emerald Mutual Fund Advisers Trust - MarketBeat
Boxer Capital Management LLC Purchases New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Tower Research Capital LLC TRC Acquires 21,145 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
TCG Crossover Management LLC Trims Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Darwin Global Management Ltd. Grows Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Nebula Research & Development LLC Has $1.14 Million Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
544,001 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Acquired by Lynx1 Capital Management LP - MarketBeat
Keros Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Was Keros Therapeutics Inc (KROS)’s session last reading good? - uspostnews.com
Implied Volatility Surging for Keros Therapeutics Stock Options - Yahoo Finance
Keros Therapeutics Inc [KROS] 10% Owner makes an insider purchase of 934,258 shares worth 9.46 million. - knoxdaily.com
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by Blue Owl Capital Holdings LP - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Russell Investments Group Ltd. - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Press Release Distribution & PR Platform - ACCESS Newswire
Geode Capital Management LLC Boosts Position in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Acquired by JPMorgan Chase & Co. - MarketBeat
Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $40.33 - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Bought by Altium Capital Management LLC - MarketBeat
197,666 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Bought by Walleye Capital LLC - MarketBeat
Alliancebernstein L.P. Decreases Stake in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
JPMorgan Chase & Co. Acquires 182,314 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Major Shareholder Purchases $9,464,033.54 in Stock - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Bought by Vanguard Group Inc. - MarketBeat
How the (KROS) price action is used to our Advantage - news.stocktradersdaily.com
Keros Therapeutics enters agreement with Pontifax By Investing.com - Investing.com India
124,620 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Acquired by Federated Hermes Inc. - MarketBeat
Keros Therapeutics enters agreement with Pontifax - Investing.com Australia
Norges Bank Invests $1.03 Million in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics Inc (KROS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Keros Therapeutics Inc 주식 (KROS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Seehra Jasbir | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
0.30 |
49,367 |
14,810 |
302,223 |
| GORDON CARL L | Director |
Aug 13 '24 |
Sale |
44.01 |
250,000 |
11,002,500 |
119,522 |
| ORBIMED ADVISORS LLC | Director |
Aug 13 '24 |
Sale |
44.01 |
250,000 |
11,002,500 |
119,522 |
0.39%
3.66%
자본화:
|
볼륨(24시간):